Xylem downgraded to Neutral from Buy at UBS

UBS downgraded Xylem (XYL) to Neutral from Buy with a price target of $132, down from $152. The firm sees near term project delay risks impacting the company’s organic growth. This makes a return to higher growth in 2026 less certain, the analyst tells investors in a research note. Following “negative peer reporting,” UBS reduced its 2026 organic growth estimate for Xylem to 1%.